M
Maggi Witmer-Pack
Researcher at Rockefeller University
Publications - 9
Citations - 2111
Maggi Witmer-Pack is an academic researcher from Rockefeller University. The author has contributed to research in topics: Viral load & Monoclonal antibody. The author has an hindex of 8, co-authored 9 publications receiving 1643 citations. Previous affiliations of Maggi Witmer-Pack include Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Marina Caskey,Florian Klein,Julio C. C. Lorenzi,Michael S. Seaman,Anthony P. West,Noreen Buckley,Gisela Kremer,Lilian Nogueira,Malte Braunschweig,Johannes F. Scheid,Joshua A. Horwitz,Irina Shimeliovich,Sivan Ben-Avraham,Maggi Witmer-Pack,Martin Platten,Clara Lehmann,Leah A. Burke,Thomas Hawthorne,Robert J. Gorelick,Bruce D. Walker,Tibor Keler,Roy M. Gulick,Gerd Fätkenheuer,Sarah J. Schlesinger,Michel C. Nussenzweig +24 more
TL;DR: It is concluded that, as a single agent, 3BNC117 is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a new modality for HIV- 1 prevention, therapy and cure.
Journal ArticleDOI
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Marina Caskey,Till Schoofs,Henning Gruell,Allison Settler,Theodora K. Karagounis,Edward F. Kreider,Ben Murrell,Nico Pfeifer,Lilian Nogueira,Thiago Y. Oliveira,Gerald H. Learn,Yehuda Z. Cohen,Clara Lehmann,Daniel Gillor,Irina Shimeliovich,Cecilia Unson-O’Brien,Daniela Weiland,Alexander. Robles,Tim Kümmerle,Christoph Wyen,Rebeka Levin,Maggi Witmer-Pack,Kemal Eren,Caroline Ignacio,Szilard Kiss,Anthony P. West,Hugo Mouquet,Barry S. Zingman,Barry S. Zingman,Roy M. Gulick,Tibor Keler,Pamela J. Bjorkman,Michael S. Seaman,Beatrice H. Hahn,Gerd Fätkenheuer,Sarah J. Schlesinger,Michel C. Nussenzweig,Michel C. Nussenzweig,Florian Klein +38 more
TL;DR: The results demonstrate the safety and activity of 10-1074 in humans and support the idea that antibodies targeting the V3 glycan supersite might be useful for the treatment and prevention of HIV-1 infection.
Journal ArticleDOI
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Johannes F. Scheid,Johannes F. Scheid,Joshua A. Horwitz,Yotam Bar-On,Edward F. Kreider,Ching-Lan Lu,Julio C. C. Lorenzi,Anna Feldmann,Malte Braunschweig,Lilian Nogueira,Thiago Y. Oliveira,Irina Shimeliovich,Roshni Patel,Leah A. Burke,Yehuda Z. Cohen,Sonya Hadrigan,Allison Settler,Maggi Witmer-Pack,Anthony P. West,Boris Juelg,Tibor Keler,Thomas Hawthorne,Barry S. Zingman,Roy M. Gulick,Nico Pfeifer,Gerald H. Learn,Michael S. Seaman,Pamela J. Bjorkman,Florian Klein,Florian Klein,Florian Klein,Sarah J. Schlesinger,Bruce D. Walker,Bruce D. Walker,Beatrice H. Hahn,Michel C. Nussenzweig,Marina Caskey +36 more
TL;DR: It is concluded that administration of 3BNC117 exerts strong selective pressure on HIV-1 emerging from latent reservoirs during ATI in humans, suggesting failure to escape over a period of 9-19 weeks.
Journal ArticleDOI
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Pilar Mendoza,Henning Gruell,Lilian Nogueira,Joy A. Pai,Allison L. Butler,Katrina G. Millard,Clara Lehmann,Isabelle Suárez,Thiago Y. Oliveira,Julio C. C. Lorenzi,Yehuda Z. Cohen,Christoph Wyen,Christoph Wyen,Tim Kümmerle,Tim Kümmerle,Theodora K. Karagounis,Ching-Lan Lu,Lisa Handl,Cecilia Unson-O’Brien,Roshni Patel,Carola Ruping,Maike Schlotz,Maggi Witmer-Pack,Irina Shimeliovich,Gisela Kremer,Eleonore Thomas,Kelly E. Seaton,Jill Horowitz,Anthony P. West,Pamela J. Bjorkman,Georgia D. Tomaras,Roy M. Gulick,Nico Pfeifer,Gerd Fätkenheuer,Michael S. Seaman,Florian Klein,Marina Caskey,Michel C. Nussenzweig,Michel C. Nussenzweig +38 more
TL;DR: It is concluded that the combination of the anti-HIV-1 monoclonal antibodies 3BNC117 and 10-1074 can maintain long-term suppression in the absence of antiretroviral therapy in individuals with antibody-sensitive viral reservoirs.
Journal ArticleDOI
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.
Yotam Bar-On,Henning Gruell,Till Schoofs,Joy A. Pai,Lilian Nogueira,Allison L. Butler,Katrina G. Millard,Clara Lehmann,Isabelle Suárez,Thiago Y. Oliveira,Theodora K. Karagounis,Yehuda Z. Cohen,Christoph Wyen,Christoph Wyen,Stefan Scholten,Lisa Handl,Shiraz A. Belblidia,Juan Dizon,Jörg Janne Vehreschild,Maggi Witmer-Pack,Irina Shimeliovich,Kanika Jain,Kerstin Fiddike,Kelly E. Seaton,Nicole L. Yates,Jill Horowitz,Roy M. Gulick,Nico Pfeifer,Georgia D. Tomaras,Michael S. Seaman,Gerd Fätkenheuer,Marina Caskey,Florian Klein,Michel C. Nussenzweig,Michel C. Nussenzweig +34 more
TL;DR: Combination of two broadly neutralizing antibodies is effective in reducing HIV-1 viremia and in limiting the emergence of resistant viral variants in individuals harboring antibody-sensitive viruses.